Press release
Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technology
Dortmund, Germany and New Jersey, USA, December 3, 2008. Protagen AG announces the closing of a cooperation contract with Bayer HealthCare AG, Leverkusen, Germany, about the evaluation of the UNIarray® technology for discovery of novel biomarkers in atrial fibrillation.Bayer HealthCare is currently investigating atrial fibrillation after heart surgery in a clinical study. A certain number of patients develop this type of cardiac symptoms after surgery. Currently, it is not possible to predict the patients at risk of developing atrial fibrillation. Aim of the proof-of-principle study is to evaluate the UNIarray® technology for discovery of novel biomarkers for patient stratification and predictive diagnosis of atrial fibrillation.
UNIarray® of Protagen is a proprietary technology platform to develop novel diagnostics based on indication-specific autoantibody patterns in blood samples from patients. These autoantibody patterns are not only present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication-specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification for clinical studies. Protagen presently is focused on research at novel diagnostics for Prostate Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Morbus Parkinson, and Alzheimer´s Disease.
About Protagen AG
Protagen AG (www.protagen.de) is a leading provider of products, services and software solutions for protein research with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented platform for development and use of protein expression libraries, and UNIchip®, a versatile and highly efficient family of products for the development of antibodies, as well as UNIarray®, unique technology base for the development of new diagnostics.
About Bayer HealthCare AG
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.
Find more information at www.bayerhealthcare.com.
Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de
Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technology here
News-ID: 61438 • Views: …
More Releases from Protagen AG
Protagen and Charles River form strategic partnership
Dortmund, Germany, October 28, 2011. Protagen AG, Dortmund, a GMP-certified specialist in the characterization of protein drugs and Charles River Laboratories International, Inc., one of the world leading companies in high-quality research models and preclinical and clinical support services, are pleased to announce a strategic Marketing & Sales alliance.
For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range…
Protagen and OncoTyrol form strategic alliance to validate the UNIarray® techno …
Dortmund, Germany and New Jersey, USA, June 10, 2009. Protagen AG and the Medical University Innsbruck, Department of Urology, have recently identified autoantigen candidates present in serum of patients with prostate cancer using the proprietary UNIArray® technology platform. In Europe, prostate cancer is the second most frequent lethal malignancy in men. Yearly about 40,000 men die of prostate cancer in the European Union.
Current standard of screening for prostate…
Protagen meets with FDA
Dortmund, Germany and New Jersey, USA, February 19, 2009. Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces that it participated in two meetings with FDA personnel during the week of January 26, 2009. The meetings were intended to provide a detailed introduction to the company’s UNIarray® technology position and its potential use in the development of novel diagnostics for multiple sclerosis…
Winner Consortium “NeuroAllianz” in the BioPharma Competition counts on UNIa …
Dortmund, Germany and New Jersey, USA, October 9, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips has won the BMBF’s BioPharma competition jointly with consortium “NeuroAllianz”. The twelve project partners will develop therapeutic as well as diagnostic approaches in the field of neurodegenerative diseases from bench to market under the direction of Professor Christa E. Mueller and Professor Alexander Pfeifer. Protagen…
More Releases for Bayer
Radiopharmaceuticals Market 2022 Sales Revenue - Bracco Imaging, Bayer, Mallinck …
Global Radiopharmaceuticals Market from 2022 to 2028 launched by MarketsandResearch.biz comprises a comprehensive market analysis that encompasses key aspects of the industry and defines current market dynamics in detail. It assesses growth patterns, magnitudes, and specific business developments under the current market scenario. The best statistical surveying and investigation performed with the advanced tools and techniques in this report. The study report shows a balanced presentation of statistical and theoretical…
Point of Care Molecular Diagnostics Market Industry Analysis with Abaxis, Inc., …
The Point of Care Molecular Diagnostics Market is set to exceed USD 2.5 billion by 2024; according to a new research study published by Global Market Insights, Inc. Increasing awareness regarding pre-disease diagnosis along with growing incidence of infectious diseases will drive point of care molecular diagnostics market growth. Growing R&D focused on reducing time required for molecular tests will further propel industry growth. However, long product development time and…
Drug Delivery Market 2018 | Johnson, Bayer
Report Summary
The Global Drug Delivery Market Size is primarily driven by the increasing demand for technological advanced products that are used for drug delivery, and increased number of chronic diseases in the increasing number of geriatric population.
Drug delivery is referred as drug administration in the human body through injections or various other devices. Drug delivery devices are used to inject the therapeutic substances in the body with the help of…
Bayer Crop Sciences Ltd
Bayer Crop Sciences Ltd
Bayer Crop Sciences Ltd- Company Profile & Financial Analysis” contains in depth information and data about the company and its operations. You will find information on the business structure, areas of operation, products and services offered by the company. It also comprises SWOT analysis, key ratios, historical financial data and insider’s view on financial stability and industrial ranking with financial forecasts for two- year period.
This report is…
Acarbose Market Share 2017-2022 Emcure, Pfizer, Takeda, Bayer Vital, Beijing Bay …
Recently Researched "Global Acarbose Market" by Material, Application, and Geography – Global Acarbose Market Forecast to 2021 is a professional and comprehensive research report. Acarbose Market describe the Acarbose market trends for the next five years. The global Acarbose market is valued at USD XX million in 2017 and Acarbose Market is projected to reach USD XX million by the end of 2021, Acarbose Industry growing at a CAGR of…
Global Spirotetramat Market 2017 : Bayer CropScience
Top Manufacture Analysis Of Spirotetramat Market 2017 Includes Market outline, section by Application, Market by Region and Production, Revenue (Value), worth Trend by kind. The Markets And analysis study delivers necessary information and realistic data of the globe Spirotetramat market. The report presents a deep study of the market growth factors and drivers. In-depth analysis of the Spirotetramat Market limitations and thus the opportunities modify the user to create the…
